Description: Mirum Pharmaceuticals, Inc., a clinical-stage therapeutics company, develops and produces therapies for patients with cholestatic liver diseases with a focus on rare pediatric conditions. The company's lead product candidate is maralixibat, a Phase 3-ready investigational oral drug with indications, including Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC). It is also developing Volixibat, an investigational oral inhibitor of ASBT, a protein that is primarily responsible for recycling bile acids from the intestine to the liver. The company was incorporated in 2018 and is based in Foster City, California.
Home Page: www.mirumpharma.com
MIRM Technical Analysis
950 Tower Lane
Foster City,
CA
94404
United States
Phone:
650 667 4085
Officers
| Name | Title |
|---|---|
| Mr. Christopher Peetz | Pres, CEO & Director |
| Dr. Ian Clements | Chief Financial Officer |
| Mr. Peter Radovich M.B.A., Ph.D. | Chief Operating Officer |
| Mr. Paul K. Ross | Chief Compliance Officer |
| Ms. Erin Campany | Sr. VP of HR |
| Dr. Pamela Vig Ph.D. | Head of R&D |
| Ms. Lara Longpre MBA, MSC | Chief Devel. Officer |
| Ms. Vinita P. Kumar | Sr. vice Pres of Quality |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.955 |
| Price-to-Sales TTM: | 12.5994 |
| IPO Date: | 2019-07-18 |
| Fiscal Year End: | December |
| Full Time Employees: | 194 |